ALRT Joins Singapore’s War on Diabetes, Commercializes Next Generation Diabetes Management Solution - Seite 2

In advance of launching sales initiatives on November 16, Diabetes Singapore recently showcased the ALRT Diabetes Solution at an invitation-only event attended by more than 100 guests on October 31, 2020. A lively Q&A session was part of the presentation, during which participants eagerly engaged ALRT management to learn more about how the system works and how it is implemented.

This event was strategically planned in advance of a larger event scheduled for World Diabetes Day on November 14, 2020 that will feature the ALRT Diabetes Solution to more than 1,000 attendees actively involved in the diabetes management market.

“Legacy strategies and even new user-facing app technologies simply aren’t moving the needle in diabetes care and everyone knows it. That is why we expect strong demand for our next-generation technology,” continued Mr. Chan. “Our emphasis is on using science and technology to lower A1C and contain complications due to diabetes right at the outset. If a diabetes patient can keep their A1C below 7% consistently, the irreversible complications due to poorly managed diabetes can be mitigated. We believe Singapore is the first step in the ALRT Diabetes Solution one day becoming the global standard of diabetes care.”

Singapore: Gateway to ASEAN Diabetes Market

Singapore is one of the 39 countries and territories of the IDF Western Pacific (WP) Region. This region has the largest population of all IDF regions and accounts for 37% of all global diabetes cases. 463 million people have diabetes in the world and 163 million people in the WP Region, a figure that is estimated to rise to 212 million by 2045.

Specific to Singapore, diabetes is a prominent problem, affecting approximately 640,400 adults, or about 14.2% of the country’s adult population. Although the total population is relatively small, Singapore is a vital beachhead into the ASEAN (Association of Southeast Asian Nations) market, comprising some 650 million people. This island republic is a major research and development center for the global pharmaceutical industry.

About ALR Technologies Inc.
ALR Technologies is a medical device company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies Inc. can be found at www.alrt.com.